Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Pre-Operative Chemotherapy as an Alternative to Post-Operative Chemo: Evidence of Stage-Dependent Survival Benefit
Author
Howard (Jack) West, MD

In contrast with post-operative chemotherapy, which has become a standard treatment approach to reduce the probability of recurrence of resected stage II and IIIA NSCLC (still pretty controversial for stage IB), pre-operative chemotherapy (also known as neoadjuvant, or induction chemotherapy) is less well studied and isn’t a typical approach. However, a recent study called ChEST, the Chemotherapy in Early Stages Trial, was presented at ASCO (abstract here) and showed a borderline positive survival benefit with neoadjuvant chemotherapy, despite the fact that the trial was stopped very early. As a trial of chemo followed by surgery vs. initial chemo followed by surgery, and post-operative chemotherapy had been shown in several trials to improve survival in this population, the Data Safety Monitoring Board felt it was unethical to continue a trial in which half the patients receive no opportunity for chemo either before or after surgery.

As shown below, the trial enrolled 270 of an initially planned 700 patients before closing early, and these patients were randomized to receive upfront surgery or three cycles of cisplatin/gemcitabine followed by surgery:

ChEST Schema

Importantly, more than half of the patients enrolled had stage IB or IIA disease. As you’d expect, this group has a better prognosis than patients who have stage IIB or IIIA resected NSCLC, and therefore potentially less to gain from chemo.

You’d presume that giving chemo is at least as beneficial in treating micrometastatic disease before compared with the same target of 3-4 cycles after surgery. In fact, not only are you able to administer chemo 6-8 weeks earlier, which might help by treating potential circulating tumor cells earlier, but you’d imagine that it’s easier to get your intended chemo into patients who aren’t still recovering from a major surgery. In fact, nearly all of the adjuvant chemotherapy trials show that only about 65-75% of patients get at least 3 cycles of intended chemo into them. In this trial, three cycles of preoperative chemo were able to be given as intended to about 85% of patients. This suggests that there may be a meaningful advantage of pre-operative vs. post-operative chemo in this regard.

Another potential advantage of neoadjuvant chemo is that you can get a sense of how well your treatment worked by assessing the cancer with a repeat CT, and it’s possible that patients can undergo a less extensive surgery if their tumor shrinks from pre-operative chemo: specifically, that some patients who would otherwise need an entire lung removed (pneumonectomy) will have enough tumor shrinkage that they can now just have a lung lobe removed (lobectomy). This trial showed that three cycles of cisplatin/gemcitabine was associated with a 35% response rate; importantly, the pneumonectomy rate was reduced from 24% with upfront surgery to 10% with chemotherapy beforehand.

Despite enrolling only 270 patients instead of 700, the trial showed a good trend toward improved progression-free survival in the recipients of pre-operative chemo:

ChEST PFS Curve

Neoadjuvant chemotherapy was associated with a more convincing improvement in overall survival (p = 0.053), which was 7% higher with chemo than with surgery alone:

ChEST OS Curve

These results are in the same ballpark of benefit as we’ve seen with adjuvant (post-operative) chemotherapy. But I was struck by the remarkably difference between the results for the better risk patients (stage IB and IIA) compared with those of the higher risk patients (stage IIB and IIIA). The benefits for both progression-free and overall survival were completely limited to those patients with higher risk:

ChEST PFS by stage

ChEST OS by Stage

And as we’ve covered in my last post, it looks like there may even be a detrimental effect of treating the earlier stage patients with chemotherapy.

At this point, even if neoadjuvant chemotherapy provides a clinical benefit as great as that with post-operative chemotherapy, it probably needs to emerge as significantly better than adjuvant chemotherapy to become a standard approach. There is a Spanish trial that is directly comparing pre-operative carbo/taxol to post-operative carbo/taxol (the NATCH trial, which stands for Neoadjuvant vs. Adjuvant Taxol/Carbo Hope). But just as I suspect that pre-operative chemo is at least as good as post-operative chemo, I’d really be surprised if giving the same chemo a couple of months earlier is actually going to be significantly better. So for now, pre-operative chemo for early stage NSCLC is a reasonable option but really isn’t considered a standard at this point.

Interestingly, stage IIIA NSCLC with N2 node involvement in North American is more typically treated with neoadjuvant therapy. I believe that’s partly because the benefits of neoadjuvant therapy with at least chemo were established more than a decade ago, so it is the standard that hasn’t been displaced by the new upstart of post-operative chemo. Another important factor, I believe, is that many experts recognize that many patients who go to surgery never end up getting to chemo, due to complications. In stage IIIA NSCLC, we feel that chemo is so important that you need to ensure you get it along with surgery, while in earlier stage lung cancer, the surgery is much more important than the chemo that is perhaps a modest modifier. If patients have surgical complications that preclude them from getting chemo for stage I or II disease, they’ve still gotten the treatment approach that is most critical for their potential cure.

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
That's beautiful Linda…
By JanineT GRACE … on
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on